Profile data is unavailable for this security.
About the company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
- Revenue in CHF (TTM)5.65m
- Net income in CHF-20.39m
- Incorporated2002
- Employees23.00
- LocationNewron Pharmaceuticals SpAvia Ludovico Ariosto 21BRESSO 20091ItalyITA
- Phone+39 26103461
- Fax+39 261034654
- Websitehttps://www.newron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipidor AB | 1.58m | -1.50m | 23.60m | -- | -- | 4.28 | -- | 14.99 | -0.5273 | -0.5273 | 0.5513 | 1.91 | 0.2755 | -- | 36.18 | -- | -26.25 | -- | -28.60 | -- | -- | -- | -95.28 | -- | -- | -- | 0.00 | -- | 761.11 | -- | -17.36 | -- | -- | -- |
| Biohit Oyj | 8.47m | -2.20m | 23.91m | 42.00 | -- | 3.76 | -- | 2.82 | -0.1404 | -0.1404 | 0.5399 | 0.5051 | 0.7556 | 2.49 | 5.60 | -- | -19.65 | -5.14 | -24.14 | -5.78 | 64.73 | 60.77 | -26.00 | -9.10 | 3.74 | -- | 0.05 | -- | -29.14 | 3.32 | -133.80 | -- | -41.71 | -- |
| Midatech Pharma PLC | 718.47k | -9.88m | 23.95m | 40.00 | -- | 3.29 | -- | 33.34 | -0.1315 | -0.1315 | 0.0095 | 0.0592 | 0.0568 | -- | 0.2273 | 14,400.00 | -78.17 | -30.67 | -174.36 | -36.70 | -- | -- | -1,375.52 | -1,130.83 | -- | -6.71 | 0.1779 | -- | -49.11 | -24.25 | -142.82 | -- | -25.73 | -- |
| Abliva AB | 21.69k | -10.10m | 24.10m | 8.00 | -- | 3.05 | -- | 1,111.09 | -0.2804 | -0.2804 | 0.0006 | 0.1934 | 0.002 | -- | 0.1955 | 30,571.43 | -94.64 | -50.45 | -110.92 | -59.36 | -5,306.08 | -61,920.20 | -46,584.11 | -89,377.78 | -- | -210.44 | 0.00 | -- | 61.19 | -38.73 | 22.09 | -- | -43.03 | -- |
| Moberg Pharma AB (publ) | -10.14bn | -10.14bn | 24.36m | 12.00 | -- | 0.5314 | -- | -- | -- | -- | -- | 9.94 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.012 | -- | -- | -- | -- | -- | -- | -- |
| SenzaGen AB | 926.75k | -2.86m | 24.81m | 16.00 | -- | 2.35 | -- | 26.77 | -1.32 | -1.32 | 0.4281 | 4.40 | 0.0818 | 2.64 | 4.96 | -- | -25.20 | -25.24 | -26.11 | -26.81 | 62.08 | 207.96 | -308.21 | -805.88 | 20.19 | -1,760.25 | 0.00 | -- | 192.14 | 35.41 | 45.92 | -- | -33.21 | -- |
| Bactiquant A/S | 937.89k | -673.91k | 25.46m | -- | -- | 6.09 | -- | 27.14 | -0.2607 | -0.2607 | 0.3629 | 1.62 | 0.2882 | 3.24 | 7.32 | -- | -20.71 | 13.96 | -22.74 | 16.28 | 5.73 | -- | -71.85 | 39.46 | 9.35 | -73.84 | 0.00 | -- | -64.62 | -- | -135.01 | -- | -- | -- |
| Predilife SA | 69.23k | -3.27m | 25.76m | 18.00 | -- | -- | -- | 372.15 | -0.8665 | -0.8665 | 0.0181 | -0.322 | 0.019 | -- | 2.32 | 5,650.21 | -89.91 | -- | -122.82 | -- | 21.24 | -- | -4,729.25 | -- | -- | -13.23 | 1.29 | -- | 125.49 | -- | -7.06 | -- | -- | -- |
| Newron Pharmaceuticals SpA | 5.65m | -20.39m | 27.60m | 23.00 | -- | 3.05 | -- | 4.89 | -1.14 | -1.14 | 0.3166 | 0.5077 | 0.1109 | -- | 3.54 | 245,638.50 | -40.03 | -25.78 | -43.68 | -28.47 | 97.21 | 78.74 | -360.85 | -223.51 | -- | -6.15 | 0.7563 | -- | -25.29 | 18.24 | -3.91 | -- | -11.37 | -- |
| Herantis Pharma Oyj | 0.00 | -13.16m | 27.79m | -- | -- | -- | -- | -- | -1.20 | -1.20 | 0.00 | -0.036 | 0.00 | -- | -- | -- | -121.29 | -50.54 | -173.91 | -58.09 | -- | -- | -- | -110,423.80 | -- | -17.32 | 1.05 | -- | -- | -- | -14.35 | -- | -- | -- |
| Farmsintez PAO | 5.40m | -8.02m | 27.91m | 119.00 | -- | 2.13 | -- | 5.17 | -2.22 | -2.22 | 1.50 | 2.48 | 0.2081 | 2.95 | 1.43 | -- | -30.88 | -18.17 | -58.42 | -23.49 | 45.85 | 44.61 | -148.38 | -157.46 | 0.2328 | -6.36 | 0.465 | -- | 27.68 | 2.32 | 71.03 | -- | -7.89 | -- |
| Corline Biomedical AB | 644.46k | -576.65k | 29.63m | 8.00 | -- | 3.13 | -- | 45.97 | -0.2816 | -0.2816 | 0.3287 | 4.35 | 0.0824 | -- | 14.19 | 794,750.00 | -7.37 | -14.05 | -7.81 | -15.57 | 154.92 | 406.13 | -89.48 | -463.81 | -- | -436.62 | 0.00 | -- | 247.37 | 28.94 | 23.62 | -- | 12.68 | -- |
| Klaria Pharma Holding AB (publ) | 0.00 | -3.18m | 30.14m | -- | -- | 3.12 | -- | -- | -0.6229 | -0.6229 | 0.00 | 1.84 | 0.00 | -- | -- | -- | -25.77 | -21.16 | -31.44 | -22.85 | -- | -- | -- | -2,113.80 | -- | -6.75 | 0.00 | -- | -100.00 | -- | -128.71 | -- | -- | -- |
| Veg of Lund AB (publ) | 164.21k | -1.80m | 30.23m | -- | -- | 11.20 | -- | 184.12 | -1.59 | -1.59 | 0.147 | 2.18 | 0.0697 | 0.6716 | 4.56 | -- | -76.43 | -- | -96.79 | -- | 24.51 | -- | -1,095.99 | -- | 3.68 | -46.60 | 0.1707 | -- | -42.25 | -- | -29.77 | -- | -- | -- |
| Magle Chemoswed Holding AB | 13.86m | 261.72k | 31.64m | -- | 122.86 | 2.25 | 22.71 | 2.28 | 0.2352 | 0.2352 | 12.94 | 12.85 | 0.6426 | 1.09 | 6.22 | -- | 1.21 | -- | 1.55 | -- | 84.45 | -- | 1.89 | -- | 0.823 | 21.86 | 0.2173 | -- | 11.58 | -- | 143.51 | -- | -- | -- |
Data as of Jan 18 2022. Currency figures normalised to Newron Pharmaceuticals SpA's reporting currency: Swiss Franc CHF
6.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aviva Investors Global Services Ltd.as of 10 Aug 2020 | 493.60k | 2.77% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2021 | 186.11k | 1.04% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020 | 173.17k | 0.97% |
| UBS Asset Management Switzerland AGas of 05 Jan 2022 | 146.25k | 0.82% |
| TOBAM SASas of 31 Dec 2020 | 51.25k | 0.29% |
| Pictet Asset Management SAas of 31 Aug 2021 | 29.73k | 0.17% |
| BlackRock Asset Management Schweiz AGas of 06 Jan 2022 | 25.34k | 0.14% |
| Lombard Odier Asset Management (Switzerland) SAas of 30 Sep 2021 | 15.24k | 0.09% |
| Dimensional Fund Advisors Ltd.as of 31 May 2021 | 7.15k | 0.04% |
| DWS CH AGas of 30 Nov 2020 | 6.25k | 0.04% |
More ▼
Data from 30 Sep 2021 - 13 Jan 2022Source: FactSet Research Systems Inc.
